CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
20 hedge funds and large institutions have $910K invested in CASI Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
11% more funds holding
Funds holding: 18 → 20 (+2)
0.18% less ownership
Funds ownership: 2.07% → 1.89% (-0.18%)
54% less capital invested
Capital invested by funds: $1.98M → $910K (-$1.07M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howland Capital Management
Boston,
Massachusetts
|
+$218K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$64.6K |
| 3 |
Renaissance Technologies
New York
|
+$41.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$3.07K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
-$220K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$144K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$93.9K |
| 4 |
Jane Street
New York
|
-$89.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.75K |
CASI Hedge Fund Activity: Q1 2024 in Review
20 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2024, worth a combined $910K — down 54% from $1.98M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CASI positions and 4 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Howland Capital Management, opening a new position worth an estimated $218K. The largest seller was Wellington Shields Capital Management, cutting an estimated $220K.
- 20 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2024, up from 18 in Q4 2023.
- Funds reported $910K of CASI Pharmaceuticals stock for Q1 2024, down 54% quarter-over-quarter.
- 6 funds opened new CASI Pharmaceuticals positions in Q1 2024 and 4 closed out, a net change of +2 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2024 was Howland Capital Management, an estimated $218K added.
- The largest CASI Pharmaceuticals seller in Q1 2024 was Wellington Shields Capital Management, an estimated $220K sold.
Based on aggregated 13F filings for Q1 2024.